Navigation Links
Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors

BOULDER, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced the appointment of Eric K. Rowinsky, M.D., and Martin Cannon to the Company's Board of Directors. Dr. Rowinsky is Senior Vice President and Chief Medical Officer for ImClone Systems, Inc. Mr. Cannon is the President and Chief Executive Officer for New Health Sciences, Inc.

The Company also announced that Arthur Hayes, Jr., M.D. has resigned from Tapestry's Board after eleven years of service. Dr. Hayes informed the Company that his resignation is due to other fiduciary obligations which might potentially interfere with his duties as a Tapestry director.

"We welcome the wealth of oncology drug development and business management experience that Dr. Eric Rowinsky and Martin Cannon are bringing to our board," commented Leonard Shaykin, Chairman and Chief Executive Officer. "We also wish Dr. Hayes the very best in his future endeavors. Arthur is a dear friend of the Company and a man of great integrity; we will miss his counsel."

Dr. Rowinsky is Senior Vice President and Chief Medical Officer for ImClone Systems, Inc. where he is focusing exclusively on the development of novel cancer therapeutics. Previously Dr. Rowinsky served as Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio and the SBC Endowed Chair for Early Drug Development. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio. Prior to that, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. He was a longstanding National Cancer Institute principal investigator, integrally involved in pivotal clinical and preclinical investigations which led to the development of both classical chemotherapeutics and targeted therapies including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, and gefitinib, among others. Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and/or Editorial Board Member of Cancer Research, Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published over 270 manuscripts in both the preclinical and clinical research fields. Dr. Rowinsky's honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He also served on the Board of Scientific Counselors of the NCI.

Martin Cannon, prior to his appointment as President and Chief Executive Officer of New Health Sciences, Inc., a company developing technology for diagnosis and management of neuro-degenerative diseases, was Executive Vice President at Commerce One, where he was responsible for all business consulting divisions and all of the company's E-Commerce exchanges. He was also founder of Cannon Associates, a consulting firm focused on high growth opportunities in new technologies and emerging markets, including extensive work in clinical diagnostics and therapeutics in the US and internationally. Previously he was a Partner at the management consulting firms AT Kearney and Bain and Company, leading major multiyear growth and profit improvement programs for numerous Fortune 500 companies in healthcare and life sciences.

Dr. Arthur Hayes commented: "I have enjoyed my tenure on Tapestry's Board and continue to believe strongly in the Company. From this point on I will be cheering from the sidelines."

About Tapestry Pharmaceuticals, Inc.

Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, TPI 287 is in multiple Phase 2 clinical studies at this time.

For more information about Tapestry and its technologies, visit Tapestry's website at


Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer


Investor: Lilian Stern

Stern Investor Relations, Inc.


Media: Dana Conti

Schwartz Communications


SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Purple: The Hottest Color for Fall in Shoes, Handbags and Martinis
2. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
3. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
4. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Richard Greco Joins Mediware Board
8. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
9. Accident Fund Will Make Board of Water & Lights Ottawa Street Station Power Plant in Lansing Its New National Headquarters
10. Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers
11. Montana Health Care Leader Elected Board Chair of National Association
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Hope; A Commitment to Cure last night at the Mandarin Oriental in New ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Vision Group ... Vision of San Diego, California. With brands including The LASIK Vision Institute and TLC ... making it the nationwide leader in laser vision correction. , Global Laser Vision will ...
(Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare Group , ... its partnership with WPC Healthcare , a provider of predictive analytics solutions ... data into an aggregated data repository necessary to perform reporting and analytics on ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... YORK , Oct. 13, 2015 Pomerantz ... filed against Amicus Therapeutics, Inc. ("Amicus" or the "Company")(NASDAQ: ... filed in United States District Court, District of ... a class consisting of all persons or entities who ... 1, 2015 inclusive (the "Class Period"). This class action seeks ...
(Date:10/13/2015)... , Oct. 13, 2015  Vitamin Angels – ... and mothers in need of nutritional support - announced ... by the United Nations (UN). The UN,s newly established ... – are a recent follow up to the Millennium ... deadline for completion. The new 17 Global Goals intend ...
(Date:10/13/2015)... , Oct. 13, 2015   Generational Equity ... middle-market businesses, is pleased to announce the acquisition of ... in Largo, Florida , by Meridian ... on September 11, 2015. Florida ... --> Florida . To learn ...
Breaking Medicine Technology: